跳至主要内容
临床试验/NCT07179341
NCT07179341已完成不适用

Survival Nomogram for Patients With Thymic Carcinoma

Weijie Ye1 个研究点 分布在 1 个国家目标入组 156 人开始时间: 2024年7月9日最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
发起方
入组人数
156
试验地点
1
主要终点
Overall survival

研究概览

简要总结

Background Thymic carcinoma (TC) is a rare and aggressive mediastinal malignancy with poor prognosis. Our study aimed to develop a nomogram to predict overall survival (OS) of TC patients.

Method A total of 156 patients confirmed TC between 1996 and 2023 were selected from our database. They were divided into training cohort, validation cohort one and validation cohort two. A nomogram was constructed based on the risk factors affecting prognosis using a Cox proportional hazards regression model. The discrimination and calibration of the nomogram were evaluated by C-index, AUC and curve of calibration. The three cohorts were divided into low-risk and high-risk subgroups.

研究设计

研究类型
Interventional
分配方式
Non Randomized
干预模型
Parallel
主要目的
Treatment
盲法
None

入排标准

性别
All
接受健康志愿者

入选标准

  • The diagnosis of TC in patients should be confirmed through endoscopic tumor biopsy or surgery to obtain tumor tissue for pathological confirmation under light microscope, and even further confirmed through immunohistochemical staining.
  • Patients should accept surgery and obtain complete postoperative pathological reports in order to assess Masaoka-Koga staging.
  • Patients who accepted surgery should be followed up at least six months or reached the endpoint event.

排除标准

  • The patient had two types of primary tumors concurrently including TC.
  • The tumor in the thymus was not primary but metastatic, having originated from a different primary site.
  • The patient did not obtain a complete pathological report after surgery.

结局指标

主要结局

Overall survival

时间窗: From date of accepting surgery until the date of final documented or date of death from any cause, whichever came first, assessed up to 325 months

Overall survival (OS) is the length of time a patient lives after a diagnosis or the start of treatment for a disease, such as cancer

次要结局

未报告次要终点

研究者

发起方
Weijie Ye
申办方类型
Other
责任方
Sponsor Investigator
主要研究者

Weijie Ye

Resident Doctor

Sun Yat-sen University

研究点 (1)

Loading locations...

相似试验